20 results about "Palindrome" patented technology

The invention discloses a system for detecting viral nucleic acid on the basis of a CRISPR (clustered regularly spaced short palindromic repeat) technology and an FET (field effect transistor) chip and application of the system, and relates to a method for detecting the viral nucleic acid on the basis of clustered CRISPR (clustered regularly spaced short palindromic repeat) and related proteins (Cas) and a field effect transistor (FET). The CRISPR-FET (clustered regularly interspaced short palindromic repeats-field effect transistor) detection system comprises a non-amplified CRISPR system, a reporter RNA (ribonucleic acid) and gold nanoparticles (AuNPs) connection system, a separation system and a field effect transistor chip detection system. The CRISPR-FET detection method provided by the invention has high sensitivity and high specificity on virus nucleic acid detection, and the lower limit of detection reaches a single copy (100 copies / [mu] L).

A method for multiplex nucleic acid detection based on clustered regularly interspaced short palindromic repeat (CRISPR), a system, and a kit for detecting a target nucleic acid based on CRISPR are provided. The detection method includes: adding any one, any two, any three, or four from the group consisting of a first nucleic acid detection composition, a second nucleic acid detection composition, a third nucleic acid detection composition, and a fourth nucleic acid detection composition to a reaction system with a target nucleic acid to achieve the multiplex detection of the target nucleic acid.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, the invention provides a Cas12j mutant protein with improved editing activity and application thereof, and the Cas12j mutant protein has a wide application prospect.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, Cas9 or smaller Cas-SF01 (a Cas12i3 variant) is utilized to reasonably design and construct a compact mRNA-delivered epigenetic suppressor in an engineering manner, and an optimized mRNA structure, lipid nanoparticle (LNP) delivery, OFF-E-V2 mRNA optimized by single intravenous injection and selected guide RNA (gRNA) targeting mouse PCSK9 are combined, so that circulating PCSK9 protein is reduced by about 90%, corresponding LDL-C level is reduced by about 55%, and the PCSK9 protein is reduced by about 90%. The effect lasts for at least 180 days. Compared with a corresponding object based on Cas9, an editor based on Cas-SF01 shows higher specificity, and off-target methylation events are fewer. The optimized LNP formulations also exhibit good safety. These findings establish a powerful and versatile platform for promoting a transient delivery-based engineered mRNA editor to achieve precise and lasting epigenetic silencing in vivo therapy.

1. Name of the product in this design: Embossed shelf (palindrome). 2. Purpose of this design: For use in the production assembly of mobile shelving units. 3. The key design features of this product are its overall shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present disclosure relates to a method of constructing a synthetic enhancer comprising: identifying probable palindromic subsequences in a promoter of interest; selecting and extracting highly palindromic subsequences from amongst the probable palindromic subsequences; and concatenating some or all of the extracted highly palindromic subsequences to produce a synthetic enhancer. Identifying the probable palindromic subsequence includes defining a candidate subsequence in the promoter of interest; generating a complement or reverse complement of the candidate subsequence; comparing the candidate subsequence with its complement or reverse complement to identify the number of mismatches; and identifying the candidate subsequence as a probable palindromic subsequence if the number of mismatches is the same or lower than a mismatch threshold corresponding to the number of mismatches expected from comparable randomly generated sequences. The method can be applied to create a synthetic enhancer for any promoter of interest.

The invention discloses a palindromic mediated self-assembly DNA molecule as well as a preparation method and application thereof, and belongs to the technical field of biology. The palindromic mediated self-assembled DNA molecule is obtained by self-assembling an A1 chain, an L1 chain and a C1 chain; the nucleotide sequence of the chain A1 is as shown in SEQ ID NO. 1; the nucleotide sequence of the L1 chain is as shown in SEQ ID NO. 2; and the nucleotide sequence of the C1 chain is as shown in SEQ ID NO. 3. The palindromic mediated self-assembled DNA molecule A1-L1-C1 disclosed by the invention can be used for detecting miR-21, and has relatively high detection sensitivity and specificity. The A1-L1-C1 also has a drug loading function, and can target specific tumor cells and accurately deliver drugs into cancer cells. The invention provides a new technical approach for early diagnosis of tumors, detection of intracellular biomolecules and targeted drug delivery, and has a wide application prospect.

The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and / or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.

The present application belongs to the field of nucleic acid editing, in particular, the field of clustered regularly interspaced short palindromic repeats (CRISPR) technology. Specifically, the present application provides a Cas mutant protein with improved activity and increased editing efficiency. Compared with the wild-type parent Cas protein, the Cas mutant protein of the present application has significantly improved activity and has a wide application prospect.

The present application belongs to the field of nucleic acid editing, in particular, the field of clustered regularly interspaced short palindromic repeats (CRISPR) technology. Specifically, the present application provides a Cas mutant protein with improved activity and increased editing efficiency. Compared with the wild-type parent Cas protein, the Cas mutant protein of the present application has significantly improved activity and has a wide application prospect.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, the invention provides adenosine deaminase which is fused with DNA binding protein, can be used for single base editing of target nucleic acid, and has a wide application prospect.

Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) systems for use as a medicament, the CRISPR system comprising a guide RNA (gRNA) comprising the sequence set forth in any one of SEQ ID NO: 3-74, and a CRISPR-associated endonuclease, the gRNAs targeting the Neh4 and / or Neh5 domain of NRF2. Also disclosed herein are methods of using the aforementioned gRNAs, DNA sequences encoding such gRNAs, and vectors and pharmaceutical compositions comprising such gRNAs.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, the invention provides a novel Cas enzyme, and the Cas enzyme belongs to a class of novel Cas proteins and has a wide application prospect.

The present application belongs to the field of nucleic acid editing, in particular to the field of clustered regularly interspaced short palindromic repeats (CRISPR) technology. Specifically, the present application provides a Cas12j mutant protein with improved editing activity and its application, which has a wide application prospect.

The present disclosure relates to methods and systems for improved specificity and / or efficiency of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system. In particular, the present disclosure provides systems and methods for increasing specificity and efficiency of CAST system by: modulating TnsC function and abundance; modulating TnsB function and abundance; and influencing CAST target preference.

This invention belongs to the field of nucleic acid editing, particularly the field of regularly clustered short palindromic repeats (CRISPR). Specifically, this invention provides a Cas mutant protein with broad application prospects.

Systems, methods, and compositions used for the control of the timing of gene expression and activation involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas and components thereof are provided. Inducible CRISPR-Cas systems having high dynamic range and reduced background or "leaky" expression in the off state are provided.

This invention relates to recombinant nucleic acid constructs encoding Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and transposon 7-like (Tn7-like) transposon systems for DNA integration, as well as methods of using the same.

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regular clustering interval short palindromic repeat (CRISPR). Specifically, the invention provides the application of the truncated HNH structural domain in improving the Cas protein editing efficiency, and the truncated HNH structural domain has a wide application prospect.